Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Acquires 238,248 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan acquired 238,248 shares of Ventyx Biosciences stock in a transaction on Friday, November 22nd. The shares were bought at an average cost of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the purchase, the chief executive officer now directly owns 1,913,276 shares of the company’s stock, valued at $3,501,295.08. The trade was a 14.22 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Raju Mohan also recently made the following trade(s):

• On Monday, November 25th, Raju Mohan bought 261,752 shares of Ventyx Biosciences stock. The stock was bought at an average price of $2.01 per share, with a total value of $526,121.52.

Ventyx Biosciences Price Performance

VTYX stock opened at $2.06 on Tuesday. Ventyx Biosciences, Inc. has a 12 month low of $1.67 and a 12 month high of $11.48. The firm’s 50-day moving average is $2.19 and its 200 day moving average is $2.64. The company has a market capitalization of $145.66 million, a PE ratio of -0.87 and a beta of 0.37.

Wall Street Analyst Weigh In

VTYX has been the topic of several recent research reports. Wells Fargo & Company decreased their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Trading of Ventyx Biosciences

Several institutional investors and hedge funds have recently modified their holdings of VTYX. Palumbo Wealth Management LLC purchased a new position in Ventyx Biosciences during the 3rd quarter worth $26,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after buying an additional 5,310 shares during the period. SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences during the 2nd quarter worth $32,000. Intech Investment Management LLC purchased a new position in shares of Ventyx Biosciences during the third quarter valued at $42,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares in the last quarter. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.